Skip to content
Governance Register

← US public companies

Spiegelman Daniel K

SEC-identified person · CIK 1238403 Identifier-verified

Public-company roles (from insider filings)

CompanyCapacity as filedFilings
vTv Therapeutics Inc. VTVT Director filed 2024 - 2026
Maze Therapeutics, Inc. MAZE Director filed 2025 - 2026
Spruce Biosciences, INC. SPRB Director filed 2020 - 2026
Kyverna Therapeutics, Inc. KYTX Director filed 2024 - 2025
Myriad Genetics INC MYGN Director filed 2020 - 2024
Jiya Acquisition Corp. JYAC Director filed 2020 - 2020
Biomarin Pharmaceutical INC BMRN EVP, Chief Financial Officer filed 2012 - 2019
Oncothyreon Inc. ONTY Director filed 2008 - 2018
Relypsa Inc RLYP Director filed 2014 - 2016
Anthera Pharmaceuticals Inc ANTH Director filed 2010 - 2014
Affymax INC AFFY Director filed 2006 - 2012
Omeros Corp OMER Director filed 2009 - 2012
Xcyte Therapies INC XYCT Director filed 2006 - 2012
CV Therapeutics INC CVTX SVP, CFO filed 2006 - 2009

All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.